Despite the promising efficacy of FXR agonists in treating NASH, nearly all of them cause side effects such as pruritus and reduced high-density lipoprotein (HDL-C)/LDL-C ratio [15]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.